ArticleScientific reports2025
ADME of Bromo-DragonFLY as an example of a new psychoactive substance (NPS) - application of in Silico methods for prediction: absorption, distribution, metabolism and excretion.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Approach to Select Lead-Like Compounds From an Opioid Class of Novel Psychoactive Substances.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromo-DragonFLY, a new psychoactive substance (NPS) within the phenethylamine class, is noted for its exceptional potency and prolonged psychoactive effects. Despite its severe toxic reactions and fatalities, research on its human metabolic fate remains limited. This study predicts the absorption, distribution, metabolism, and excretion (ADME) of Bromo-DragonFLY using in silico methods. Results indicate high gastrointestinal absorption and potential blood-brain barrier penetration, enhancing its central nervous system effects. The compound shows significant plasma protein binding and involves multiple cytochrome P450 isoenzymes in its metabolism, with variability in phase I and II reactions. Predicted metabolites form through epoxidation, quinone formation, UGT conjugation, and N-dealkylation, exhibiting reactivity with proteins, DNA, and glutathione, contributing to its toxicological profile. Excretion is predicted mainly via renal pathways. These insights are crucial for understanding the toxicological risks of Bromo-DragonFLY, exemplifying the challenges posed by NPS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.